The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Marley Spoon business combination with 468 SPAC II
![Germany Germany flag](https://www.greenhill.com/sites/default/files/germany.gif)
Advising Marley Spoon SE, an ASX listed global subscription-based meal kit provider, on its business combination agreement with 468 SPAC II, simultaneous capital raising and amendment to existing debt facilities
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Tate & Lyle PLC’s Primary Products business in North America and Latin America (50% stake)
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advising Tate & Lyle PLC, a leading UK-based global provider of food and beverage ingredients and solutions, on its sale of a controlling stake in its Primary Products business in North America and Latin America
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Australian Unity Funds Management
![flag not available](https://www.greenhill.com/sites/default/files/n_a_flag.gif)
Advised Australian Unity Funds Management on a A$320m equity raising and A$80m cash liquidity offer for Australian Unity Healthcare Property Trust
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Bionomics Limited
![flag not available](https://www.greenhill.com/sites/default/files/n_a_flag.gif)
Advised ASX-listed Bionomics, a clinical stage biopharmaceutical company focused on the treatment of serious central nervous system disorders and cancer, on a consultation process with shareholders following calls for Board change, leading to the formation of a shareholder working group of leading institutional investors and company-led Board renewal.
![Brazil Brazil flag](https://www.greenhill.com/sites/default/files/brazil.gif)
Recepta Biopharma
![Brazil Brazil flag](https://www.greenhill.com/sites/default/files/brazil.gif)
Advised Recepta Biopharma on a capital raise
![flag not available](https://www.greenhill.com/sites/default/files/n_a_flag.gif)
Refinancing of syndicated bank debt facilities
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Advised Primary Health Care on the refinancing of its A$1.25 billion syndicated bank debt facilities
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Goodman Fielder Limited
Advised Goodman Fielder Limited, an Australian consumer foods manufacturer and distributor, on its equity capital raising via a rights issue
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Bionomics Ltd
Advised Bionomics Ltd, in relation to the tender process run by Bionomics’ largest shareholder, Start-up Australia Ventures (“Start-up”), for its 28% stake in the company, follow on sell-down of Start-up’s stake to 8% and associated capital raising by Bionomics